vs
碧迪（BDX）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是瑞思迈的3.7倍（$5.3B vs $1.4B），瑞思迈净利率更高（27.6% vs 7.3%，领先20.3%），瑞思迈同比增速更快（11.0% vs -0.4%），碧迪自由现金流更多（$549.0M vs $311.2M），过去两年瑞思迈的营收复合增速更高（9.0% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
BDX vs RMD — 直观对比
营收规模更大
BDX
是对方的3.7倍
$1.4B
营收增速更快
RMD
高出11.4%
-0.4%
净利率更高
RMD
高出20.3%
7.3%
自由现金流更多
BDX
多$237.8M
$311.2M
两年增速更快
RMD
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $1.4B |
| 净利润 | $382.0M | $392.6M |
| 毛利率 | 45.9% | 61.8% |
| 营业利润率 | 10.5% | 34.6% |
| 净利率 | 7.3% | 27.6% |
| 营收同比 | -0.4% | 11.0% |
| 净利润同比 | 24.0% | 13.9% |
| 每股收益（稀释后） | $1.34 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXRMD
| Q4 25 | $5.3B | $1.4B | ||
| Q3 25 | $5.9B | $1.3B | ||
| Q2 25 | $5.5B | $1.3B | ||
| Q1 25 | $5.3B | $1.3B | ||
| Q4 24 | $5.2B | $1.3B | ||
| Q3 24 | $5.4B | $1.2B | ||
| Q2 24 | $5.0B | $1.2B | ||
| Q1 24 | $5.0B | $1.2B |
净利润BDXRMD
| Q4 25 | $382.0M | $392.6M | ||
| Q3 25 | $493.0M | $348.5M | ||
| Q2 25 | $574.0M | $379.7M | ||
| Q1 25 | $308.0M | $365.0M | ||
| Q4 24 | $303.0M | $344.6M | ||
| Q3 24 | $400.0M | $311.4M | ||
| Q2 24 | $487.0M | $292.2M | ||
| Q1 24 | $537.0M | $300.5M |
毛利率BDXRMD
| Q4 25 | 45.9% | 61.8% | ||
| Q3 25 | 47.5% | 61.5% | ||
| Q2 25 | 47.8% | 60.8% | ||
| Q1 25 | 42.8% | 59.3% | ||
| Q4 24 | 43.2% | 58.6% | ||
| Q3 24 | 45.7% | 58.6% | ||
| Q2 24 | 46.2% | 58.5% | ||
| Q1 24 | 45.7% | 57.9% |
营业利润率BDXRMD
| Q4 25 | 10.5% | 34.6% | ||
| Q3 25 | 11.8% | 33.4% | ||
| Q2 25 | 16.0% | 33.7% | ||
| Q1 25 | 10.4% | 33.0% | ||
| Q4 24 | 8.8% | 32.5% | ||
| Q3 24 | 11.4% | 31.6% | ||
| Q2 24 | 12.1% | 31.2% | ||
| Q1 24 | 14.5% | 31.3% |
净利率BDXRMD
| Q4 25 | 7.3% | 27.6% | ||
| Q3 25 | 8.4% | 26.1% | ||
| Q2 25 | 10.4% | 28.2% | ||
| Q1 25 | 5.8% | 28.3% | ||
| Q4 24 | 5.9% | 26.9% | ||
| Q3 24 | 7.4% | 25.4% | ||
| Q2 24 | 9.8% | 23.9% | ||
| Q1 24 | 10.6% | 25.1% |
每股收益（稀释后）BDXRMD
| Q4 25 | $1.34 | $2.68 | ||
| Q3 25 | $1.71 | $2.37 | ||
| Q2 25 | $2.00 | $2.58 | ||
| Q1 25 | $1.07 | $2.48 | ||
| Q4 24 | $1.04 | $2.34 | ||
| Q3 24 | $1.37 | $2.11 | ||
| Q2 24 | $1.68 | $1.97 | ||
| Q1 24 | $1.85 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $1.4B |
| 总债务越低越好 | — | $403.9M |
| 股东权益账面价值 | $25.3B | $6.3B |
| 总资产 | $54.8B | $8.5B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资BDXRMD
| Q4 25 | $740.0M | $1.4B | ||
| Q3 25 | $641.0M | $1.4B | ||
| Q2 25 | $735.0M | $1.2B | ||
| Q1 25 | $667.0M | $932.7M | ||
| Q4 24 | $711.0M | $521.9M | ||
| Q3 24 | $1.7B | $426.4M | ||
| Q2 24 | $4.5B | $238.4M | ||
| Q1 24 | $2.3B | $237.9M |
总债务BDXRMD
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | — | $662.9M | ||
| Q3 24 | — | $667.6M | ||
| Q2 24 | — | $697.3M | ||
| Q1 24 | — | $997.0M |
股东权益BDXRMD
| Q4 25 | $25.3B | $6.3B | ||
| Q3 25 | $25.4B | $6.1B | ||
| Q2 25 | $25.5B | $6.0B | ||
| Q1 25 | $25.2B | $5.5B | ||
| Q4 24 | $25.2B | $5.3B | ||
| Q3 24 | $25.9B | $5.2B | ||
| Q2 24 | $25.9B | $4.9B | ||
| Q1 24 | $25.6B | $4.6B |
总资产BDXRMD
| Q4 25 | $54.8B | $8.5B | ||
| Q3 25 | $55.3B | $8.3B | ||
| Q2 25 | $54.9B | $8.2B | ||
| Q1 25 | $54.5B | $7.6B | ||
| Q4 24 | $54.7B | $7.1B | ||
| Q3 24 | $57.3B | $7.2B | ||
| Q2 24 | $55.6B | $6.9B | ||
| Q1 24 | $54.2B | $6.8B |
负债/权益比BDXRMD
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $311.2M |
| 自由现金流率自由现金流/营收 | 10.5% | 21.9% |
| 资本支出强度资本支出/营收 | 2.1% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.72× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $1.8B |
8季度趋势，按日历期对齐
经营现金流BDXRMD
| Q4 25 | $657.0M | $339.7M | ||
| Q3 25 | $1.4B | $457.3M | ||
| Q2 25 | $1.2B | $538.8M | ||
| Q1 25 | $164.0M | $578.7M | ||
| Q4 24 | $693.0M | $308.6M | ||
| Q3 24 | $1.2B | $325.5M | ||
| Q2 24 | $1.3B | $440.1M | ||
| Q1 24 | $514.0M | $402.0M |
自由现金流BDXRMD
| Q4 25 | $549.0M | $311.2M | ||
| Q3 25 | $1.0B | $414.4M | ||
| Q2 25 | $1.0B | $508.2M | ||
| Q1 25 | $35.0M | $557.9M | ||
| Q4 24 | $588.0M | $288.0M | ||
| Q3 24 | $882.0M | $307.7M | ||
| Q2 24 | $1.1B | $415.2M | ||
| Q1 24 | $380.0M | $380.8M |
自由现金流率BDXRMD
| Q4 25 | 10.5% | 21.9% | ||
| Q3 25 | 17.0% | 31.0% | ||
| Q2 25 | 19.0% | 37.7% | ||
| Q1 25 | 0.7% | 43.2% | ||
| Q4 24 | 11.4% | 22.5% | ||
| Q3 24 | 16.2% | 25.1% | ||
| Q2 24 | 22.4% | 33.9% | ||
| Q1 24 | 7.5% | 31.8% |
资本支出强度BDXRMD
| Q4 25 | 2.1% | 2.0% | ||
| Q3 25 | 6.0% | 3.2% | ||
| Q2 25 | 3.2% | 2.3% | ||
| Q1 25 | 2.4% | 1.6% | ||
| Q4 24 | 2.0% | 1.6% | ||
| Q3 24 | 5.4% | 1.5% | ||
| Q2 24 | 3.6% | 2.0% | ||
| Q1 24 | 2.7% | 1.8% |
现金转化率BDXRMD
| Q4 25 | 1.72× | 0.87× | ||
| Q3 25 | 2.75× | 1.31× | ||
| Q2 25 | 2.12× | 1.42× | ||
| Q1 25 | 0.53× | 1.59× | ||
| Q4 24 | 2.29× | 0.90× | ||
| Q3 24 | 2.94× | 1.05× | ||
| Q2 24 | 2.66× | 1.51× | ||
| Q1 24 | 0.96× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
